Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma.
Cardenas LM, Deluce JE, Khan S, Gulam O, Maleki Vareki S, Fernandes R, Lalani AA. Cardenas LM, et al. Among authors: lalani aa. Curr Oncol. 2022 Jul 30;29(8):5426-5441. doi: 10.3390/curroncol29080429. Curr Oncol. 2022. PMID: 36005167 Free PMC article. Review.
Systemic treatments for metastatic urothelial carcinoma.
Lalani AA, Sonpavde GP. Lalani AA, et al. Expert Opin Pharmacother. 2019 Feb;20(2):201-208. doi: 10.1080/14656566.2018.1544242. Epub 2018 Nov 9. Expert Opin Pharmacother. 2019. PMID: 30412003 Review.
Response of Primary Renal Cell Carcinoma to Systemic Therapy.
Bossé D, Lin X, Simantov R, Lalani AA, Derweesh I, Chang SL, Choueiri TK, McKay RR. Bossé D, et al. Among authors: lalani aa. Eur Urol. 2019 Dec;76(6):852-860. doi: 10.1016/j.eururo.2019.08.035. Epub 2019 Oct 6. Eur Urol. 2019. PMID: 31594707
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts.
Bossé D, Xie W, Lin X, Simantov R, Lalani AA, Graham J, Wells JC, Donskov F, Rini B, Beuselinck B, Alva A, Hansen A, Wood L, Soulières D, Kollmannsberger C, Patenaude F, Heng DYC, Choueiri TK, McKay RR. Bossé D, et al. Among authors: lalani aa. JCO Glob Oncol. 2020 Feb;6:293-306. doi: 10.1200/JGO.19.00380. JCO Glob Oncol. 2020. PMID: 32109159 Free PMC article.
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA, Lalani AA, Xie W, Steinharter JA, E Bakouny Z, Martini DJ, Fleischer JH, Abou-Alaiwi S, Nassar A, Nuzzo PV, Kaymakcalan MD, Braun DA, Wei XX, Harshman LC, Bilen MA, Choueiri TK. McGregor BA, et al. Among authors: lalani aa. Eur J Cancer. 2020 Aug;135:203-210. doi: 10.1016/j.ejca.2020.05.009. Epub 2020 Jun 27. Eur J Cancer. 2020. PMID: 32599410
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL, Dudani S, Wells JC, Donskov F, Pal SK, Dizman N, Rathi N, Beuselinck B, Yan F, Lalani AA, Hansen A, Szabados B, de Velasco G, Tran B, Lee JL, Vaishampayan UN, Bjarnason GA, Subasri M, Choueiri TK, Heng DYC. Gan CL, et al. Among authors: lalani aa. Cancer Med. 2021 Feb;10(4):1212-1221. doi: 10.1002/cam4.3717. Epub 2021 Jan 18. Cancer Med. 2021. PMID: 33463028 Free PMC article.
51 results